{"doi":"10.3390/antiox10030450","title":"A Novel ALDH2 Activator AD-9308 Improves Diastolic and Systolic Myocardial Functions in Streptozotocin-Induced Diabetic Mice","abstract":"<jats:p>Diabetes mellitus has reached epidemic proportion worldwide. One of the diabetic complications is cardiomyopathy, characterized by early left ventricular (LV) diastolic dysfunction, followed by development of systolic dysfunction and ventricular dilation at a late stage. The pathogenesis is multifactorial, and there is no effective treatment yet. In recent years, 4-hydroxy-2-nonenal (4-HNE), a toxic aldehyde generated from lipid peroxidation, is implicated in the pathogenesis of cardiovascular diseases. Its high bioreactivity toward proteins results in cellular damage. Mitochondrial aldehyde dehydrogenase 2 (ALDH2) is the major enzyme that detoxifies 4-HNE. The development of small-molecule ALDH2 activator provides an opportunity for treating diabetic cardiomyopathy. This study found that AD-9308, a water-soluble andhighly selective ALDH2 activator, can improve LV diastolic and systolic functions, and wall remodeling in streptozotocin-induced diabetic mice. AD-9308 treatment dose-dependently lowered serum 4-HNE levels and 4-HNE protein adducts in cardiac tissue from diabetic mice, accompanied with ameliorated myocardial fibrosis, inflammation, and apoptosis. Improvements of mitochondrial functions, sarco/endoplasmic reticulumcalcium handling and autophagy regulation were also observed in diabetic mice with AD-9308 treatment. In conclusion, ADLH2 activation effectively ameliorated diabetic cardiomyopathy, which may be mediated through detoxification of 4-HNE. Our findings highlighted the therapeutic potential of ALDH2 activation for treating diabetic cardiomyopathy.</jats:p>","journal":"Antioxidants","year":2021,"id":679102,"datarank":0.4335557636844247,"base_score":2.8903717578961645,"endowment":2.8903717578961645,"self_citation_contribution":0.4335557636844247,"citation_network_contribution":0.0,"self_endowment_contribution":0.4335557636844247,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":17,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1774348,"name":"Siow-Wey Hee","orcid":null,"position":1,"is_corresponding":false},{"id":1774349,"name":"Chin-Feng Hsuan","orcid":null,"position":2,"is_corresponding":false},{"id":588118,"name":"Wenjin Yang","orcid":"0000-0002-6198-1979","position":3,"is_corresponding":false},{"id":1774350,"name":"Jing-Yong Huang","orcid":null,"position":4,"is_corresponding":false},{"id":1774351,"name":"Ya-Ling Lin","orcid":null,"position":5,"is_corresponding":false},{"id":1774352,"name":"Chih-Neng Hsu","orcid":null,"position":6,"is_corresponding":false},{"id":1774354,"name":"Juey-Jen Hwang","orcid":null,"position":7,"is_corresponding":false},{"id":1774355,"name":"Shiau-Mei Chen","orcid":null,"position":8,"is_corresponding":false},{"id":588530,"name":"Zhi-Zhong Ding","orcid":null,"position":9,"is_corresponding":false},{"id":588120,"name":"Tung-Yuan Lee","orcid":"0009-0001-2779-8361","position":10,"is_corresponding":false},{"id":1774357,"name":"Yu-Chiao Lin","orcid":null,"position":11,"is_corresponding":false},{"id":1774358,"name":"Feng-Chiao Tsai","orcid":"0000-0001-9615-6023","position":12,"is_corresponding":false},{"id":588531,"name":"Wei-Lun Su","orcid":null,"position":13,"is_corresponding":false},{"id":588124,"name":"Li-Yun Chueh","orcid":"0000-0002-7811-8979","position":14,"is_corresponding":false},{"id":588119,"name":"Meng-Lun Hsieh","orcid":"0000-0001-8520-5264","position":15,"is_corresponding":false},{"id":1224388,"name":"Che-Hong Chen","orcid":null,"position":16,"is_corresponding":false},{"id":1774359,"name":"Daria Mochly-Rosen","orcid":null,"position":17,"is_corresponding":false},{"id":57663,"name":"Yi-Cheng Chang","orcid":null,"position":18,"is_corresponding":false},{"id":24714,"name":"Lee-Ming Chuang","orcid":null,"position":19,"is_corresponding":false},{"id":588527,"name":"Hsiao-Lin Lee","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"A Novel ALDH2 Activator AD-9308 Improves Diastolic and Systolic Myocardial Functions in Streptozotocin-Induced Diabetic Mice","abstract":"<jats:p>Diabetes mellitus has reached epidemic proportion worldwide. One of the diabetic complications is cardiomyopathy, characterized by early left ventricular (LV) diastolic dysfunction, followed by development of systolic dysfunction and ventricular dilation at a late stage. The pathogenesis is multifactorial, and there is no effective treatment yet. In recent years, 4-hydroxy-2-nonenal (4-HNE), a toxic aldehyde generated from lipid peroxidation, is implicated in the pathogenesis of cardiovascular diseases. Its high bioreactivity toward proteins results in cellular damage. Mitochondrial aldehyde dehydrogenase 2 (ALDH2) is the major enzyme that detoxifies 4-HNE. The development of small-molecule ALDH2 activator provides an opportunity for treating diabetic cardiomyopathy. This study found that AD-9308, a water-soluble andhighly selective ALDH2 activator, can improve LV diastolic and systolic functions, and wall remodeling in streptozotocin-induced diabetic mice. AD-9308 treatment dose-dependently lowered serum 4-HNE levels and 4-HNE protein adducts in cardiac tissue from diabetic mice, accompanied with ameliorated myocardial fibrosis, inflammation, and apoptosis. Improvements of mitochondrial functions, sarco/endoplasmic reticulumcalcium handling and autophagy regulation were also observed in diabetic mice with AD-9308 treatment. In conclusion, ADLH2 activation effectively ameliorated diabetic cardiomyopathy, which may be mediated through detoxification of 4-HNE. Our findings highlighted the therapeutic potential of ALDH2 activation for treating diabetic cardiomyopathy.</jats:p>","is_dataset_classified":null,"base_score":2.8903717578961645,"endowment":2.8903717578961645,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"33805825","pmcid":"PMC7998151","openalex_id":"https://openalex.org/W3136915496","authors":[],"funders":[{"funder_name":"Ministry of Science and Technology, Taiwan","grant_id":"MOST 105-2314-B-002-105-MY3","title":null},{"funder_name":"National Taiwan University Hospital Yunlin Branch","grant_id":"NTUHYL109.S013","title":null},{"funder_name":"National Taiwan University Hospital Yunlin Branch","grant_id":"NTUHYL107.S004","title":null},{"funder_name":"Diabetes Association of R.O.C.","grant_id":"2020","title":null},{"funder_name":"NIAAA NIH HHS","grant_id":"R01 AA011147","title":null},{"funder_name":"NIAAA NIH HHS","grant_id":"R37 AA011147","title":null},{"funder_name":"National Institutes of Health","grant_id":"5R01AA011147-26","title":"Ethanol and aldehyde dehydrogenases in health and disease"}],"total_grants":7,"fwci":1.3133,"citation_percentile":0.81318233,"influential_citations":0,"citation_trend":[{"year":2022,"count":2},{"year":2023,"count":3},{"year":2024,"count":4},{"year":2025,"count":7},{"year":2026,"count":1}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/2076-3921/10/3/450/pdf?version=1616143020","host_type":"journal"},{"url":"https://www.mdpi.com/2076-3921/10/3/450/pdf?version=1616143020","host_type":"publisher"},{"url":"https://www.mdpi.com/2076-3921/10/3/450/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/antiox10030450","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/33805825","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7998151","host_type":"repository"},{"url":"https://doaj.org/article/c1b002e8a5a54d4bbb2a3a8881540c4d","host_type":"repository"},{"url":"https://dx.doi.org/10.3390/antiox10030450","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC7998151","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC7998151?pdf=render","host_type":"Europe_PMC"},{"url":"http://dx.doi.org/10.3390/antiox10030450","host_type":""}],"fields_of_study":["Cardiovascular Function and Risk Factors","Cardiac Ischemia and Reperfusion","Alcohol Consumption and Health Effects","0301 basic medicine","0303 health sciences","03 medical and health sciences"],"mesh_terms":[],"keywords":["ALDH2","Diabetic cardiomyopathy","Medicine","Internal medicine","Pathogenesis","Diabetes mellitus","Endocrinology","Cardiomyopathy","Diastole","Cardiac fibrosis","Activator (genetics)","Lipid peroxidation","Fibrosis","Aldehyde dehydrogenase","Oxidative stress","Heart failure","Chemistry","Blood pressure","Biochemistry","Enzyme","Receptor","4-Hydroxy-2-nonenal","Mitochondrial Aldehyde Dehydrogenase 2","Ad-9308","Therapeutics. Pharmacology","RM1-950","Article"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"doi"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-17T12:13:54.578170Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}